Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
1
100.0%
No approval data available
- Lobe Sciences will present Phase 1a first-in-human data for Conjugated Psilocin (L-130) at the 9th Neuropsychiatric Drug Development Summit in Boston on September 16, 2026. - The ten-subject Phase 1a results cover oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses of the patented psilocin salt. - L-130 is a patented new chemical entity delivering psilocin directly rather than as a prodrug, initially developed for cluster headache with co-development in PTSD and other disorders. - The company's strategy rests on separating therapeutic benefit from the psychedelic experience by targeting controlled exposure levels below those typically associated with hallucinations.
- Lobe Sciences is advancing L-130, a patented stabilized psilocin new chemical entity, initially targeting chronic cluster headache with an IND filing planned for late 2026. - A first-in-human safety study of L-130 completed in 2024 reported no serious adverse events and no hallucinations at the study dose. - The company's S-100 program for sickle cell disease, a proprietary fatty acid triglyceride formulation, is targeting a Phase 2 study initiation in the first half of 2027. - Lobe Sciences completed a non-brokered private placement raising approximately $950,000 to support continued advancement of its development programs.
- Lobe Sciences has obtained European Unitary Patent EP4117446 validation, providing intellectual property protection across 17 EU member states for its DHA and egg yolk-based composition targeting Sickle Cell Disease. - The patent covers the formulation underlying Altemia® Medical Food, a first-in-class emulsified oral treatment designed to restore red blood cell membrane integrity and address long-chain fatty acid deficiencies in SCD patients. - This validation strengthens Lobe's intellectual property portfolio and enables broader commercialization of Altemia® across key European markets as part of the company's global expansion strategy.
